PCSK9: a convertase that coordinates LDL catabolism Published, JLR Papers in Press, November 19, 2008.

By Jay D. Horton, Jonathan C. Cohen, Helen H. Hobbs. Journal of Lipid Research, 2009

613 citations recorded by the source corpus.

The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD). PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for degradation. Individuals with loss-of-function mutations in PCSK9 have reduced plasma levels of LDL cholesterol and are protected from CHD; these observations have validated PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention of CHD.

Subfields: Materials Chemistry, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/96988a891a3a6950f23358310822740825108cbb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

  1. M. Mbikay

Citations in the corpus